ArticleFrontiers in pharmacology2024

Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups.

Yingyong Ou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.